에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

HEALTHEQUITY INC

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FIVE

STNE

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 월스트리트는 시그넷 주얼러스(NYSE:SIG)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.

수요일 주목해야 할 주식: 윌리엄스-소노마, 헬스에퀴티, 시그넷, 스톤코 및 파이브 빌로우

Healthequity,Headquarters,In,Draper,,Utah,,Usa,,June,25,,2023.,Healthequity,

Guidance

Health Care

Analyst Ratings

Movers

Insurance

화요일(18일) 장이 마감된 후 헬스에퀴티(NASDAQ:HQY)는 4분기 실적을 발표했고 애프터마켓에서 주가는 급락하고 있다. 실적 보고서의 요약 내용은 다음과 같다.

헬스에퀴티 4분기 EPS 예상치 미달, 부진한 전망...시간외 주가 15% 급락

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

BIDU

CWCO

GETY

SAIC

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#34;극단적 공포&#34; 영역에 머물렀다.미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 &#39;극단적 공포&#39; 영역

HealthEquity Inc

U.S. stocks settled higher on Friday, with the Dow Jones index gaining more than 400 points during the session following the release of jobs data.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul class="wp-block-list">
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated an Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a price target of $500 on June 4. This analyst sees around 6% upside in the stock.</li>
<li>Recent News: CrowdStrike CEO George Kurtz recently expressed confidence in the cybersecurity company's financial practices, as the firm faces a Department of Justice inquiry related to last year's massive global IT outage and transaction reporting.</li>
</ul>
Analyst: Alexander Paris
<ul class="wp-block-list">
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Outperform rating on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) and raised the price target from $112 to $125 on June 5. This analyst sees around 12% surge in the stock.</li>
<li>Recent News: On June 3, HealthEquity reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance.</li>
</ul>
Analyst: Doug Anmuth 
<ul class="wp-block-list">
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and increased the price target from $225 to $240 on June 4. This analyst sees around 12% upside in the stock.</li>
<li>Recent News: On June 5, Amazon.com cut jobs in its books division, including roles at Goodreads and Kindle.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Neutral rating on LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) and cut the price target from $100 to $93 on June 5. This analyst sees around 90% upside in the stock.</li>
<li>Recent News: On June 4, LGI Homes reported 416 home closings in May.</li>
</ul>
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and boosted the price target from $267 to $295 on June 6. This analyst sees around 20% upside in the stock.</li>
<li>Recent News: On June 5, Broadcom reported second-quarter revenue of $15 billion, beating analyst estimates of $14.99 billion, according to Benzinga Pro.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Price Target

AMZN

AVGO

CRWD

LGIH

5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Week

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barrington Research raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $112 to $125. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares closed at $113.6 on Wednesday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from $100 to $115. Mizuho analyst David Bellinger maintained a Neutral rating. Five Below shares closed at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $124 to $130. Mizuho analyst Vijay Rakesh maintained an Outperform rating. Micron shares closed at $103.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $80 to $96. Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating. Dollar Tree Enterprise shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased the price target for Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from $86 to $103. B of A Securities analyst Omar Dessouky maintained a Buy rating. Roblox shares closed at $91.05 on Wednesday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) price target from $107 to $122. Goldman Sachs analyst Kate McShane maintained a Buy rating. Five Below shares settled at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) price target from $134 to $145. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. BioNTech shares closed at $111.14 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) price target from $8 to $9. DA Davidson analyst Clark Wright maintained a Neutral rating. Sprinklr shares closed at $9.06 on Wednesday.  <a href="https://www.benzinga.com/quote/CXM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from $23 to $22. Barclays analyst Adrienne Yih maintained an Overweight rating. Victoria&#8217;s Secret shares settled at $20.47 on Wednesday. <a href="https://www.benzinga.com/quote/VSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $52 to $59. Scotiabank analyst Brandon Bingham maintained a Sector Perform rating. Williams shares closed at $60.10 on Wednesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CRWD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MU/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png" alt="" class="wp-image-940314" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

BNTX

DLTR

RBLX

VSCO

Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $125.

Barrington Research Maintains Outperform on HealthEquity, Raises Price Target to $125

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $98 to $115.

Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $115

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) posted better-than-expected first-quarter results after Tuesday&#8217;s closing bell.
HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
"The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year," said Scott Cutler, CEO of HealthEquity.
HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74 to a new range of $3.61 to $3.78, versus the $3.63 analyst estimate. The company reiterated its 2026 revenue outlook for a range of $1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HealthEquity shares gained 9.8% to $113.94 on Wednesday.
These analysts made changes to their price targets on HealthEquity following earnings announcement.
<ul class="wp-block-list">
<li>JMP Securities analyst Constantine Davides maintained HealthEquity with a Market Outperform and raised the price target from $110 to $117.</li>
<li>B of A Securities analyst Allen Lutz maintained the stock with a Buy and raised the price target from $110 to $125.</li>
<li>RBC Capital analyst Daniel Perlin maintained HealthEquity with an Outperform rating and raised the price target from $112 to $117.</li>
<li>Goldman Sachs analyst David Roman maintained HealthEquity with a Neutral and raised the price target from $94 to $104.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

HealthEquity Analysts Boost Their Forecasts After Upbeat Earnings

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and raises the price target from $94 to $104.

Goldman Sachs Maintains Neutral on HealthEquity, Raises Price Target to $104

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results. Also, multiple firms raised their respective <a href="https://www.benzinga.com/quote/GWRE/earnings">price targets on the stock</a>.
Guidewire Software reported quarterly earnings of 88 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $293.51 million which beat the analyst consensus estimate of $286.39 million.
Guidewire Software shares jumped 19.1% to $259.83 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Ctrl Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares jumped 54% to $50.67.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 27.8% to $8.71 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 22.7% to $12.58.</li>
<li>REV Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) rose 16.7% to $43.45 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.8% to $36.05.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) rose 15.2% to $17.05 after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) jumped 15.2% to $3.1800.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 13.5% to $6.74. Navitas Semiconductor recently announced it has entered a partnership with BrightLoop for hydrogen fuel-cell charge.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) gained 11.1% to $28.50.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 10% to $670.00. Regencell Bioscience recently announced a 38-for-1 forward stock split.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) gained 9.2% to $113.30 after the company reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) rose 8.6% to $79.70.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 7.5% to $83.47 after the company raised its fourth-quarter guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 7.5% to $3.7997.</li>
</ul>
Now Read This<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Intraday Update

APLD

GWRE

LITE

MCTR

NVTS

REVG

YEXT

ZLAB

Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS raised Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) price target from $120 to $128. UBS analyst Michael Lasser maintained a Buy rating. Dollar General shares closed at $112.62 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/DG/analyst-ratings">view this stock</a>.</li>
<li>Mizuho boosted the price target for Viper Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) from $54 to $55. Mizuho analyst William Janela maintained an Outperform rating. Viper Energy shares closed at $41.41 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/VNOM/analyst-ratings">view this stock</a>.</li>
<li>Goldman Sachs raised XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) price target from $17 to $23. Goldman Sachs analyst Tito Labarta upgraded the stock from Neutral to Buy. XP shares closed at $19.33 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/XP/analyst-ratings">view this stock</a>.</li>
<li>UBS raised the price target for Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from $16 to $18. UBS analyst David Vogt maintained a Neutral rating. Hewlett Packard Enterprise shares closed at $17.68 on Tuesday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital increased the price target for Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) from $189 to $231. RBC Capital analyst Mike Dahl maintained an Outperform rating. Ferguson shares closed at $211.53 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) price target from $135 to $160. B of A Securities analyst Brad Sills maintained an Underperform rating. Guidewire shares settled at $218.13 on Tuesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) price target from $100 to $130. Wells Fargo analyst Joe O&#8217;Dea maintained an Overweight rating. Johnson Controls shares closed at $101.18 on Tuesday. <a href="https://www.benzinga.com/quote/JCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $110 to $117. JMP Securities analyst Constantine Davides maintained a Market Outperform rating. HealthEquity shares closed at $103.76 on Tuesday.  <a href="https://www.benzinga.com/quote/hqy/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) from $70 to $75. Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating. Signet shares settled at $75.24 on Tuesday. <a href="https://www.benzinga.com/quote/sig/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $83 to $90. B of A Securities analyst Erika Najarian maintained a Buy rating. Wells Fargo shares closed at $75.65 on Tuesday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/WFC/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png" alt="" class="wp-image-938410" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

FERG

VNOM

Wells Fargo To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.

RBC Capital analyst Daniel Perlin maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $117.

RBC Capital Maintains Outperform on HealthEquity, Raises Price Target to $117

10 analysts have shared their evaluations of HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $110.9, with a high estimate of $125.00 and a low estimate of $94.00. Observing a downward trend, the current average is 1.47% lower than the prior average price target of $112.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1749045618_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of HealthEquity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$117.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>All You Need to Know About HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Financial Milestones: HealthEquity's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.46%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HealthEquity's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.76%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 10 Analysts

B of A Securities analyst Allen Lutz maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $110 to $125.

B of A Securities Maintains Buy on HealthEquity, Raises Price Target to $125

JMP Securities analyst Constantine Davides maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Market Outperform and raises the price target from $110 to $117.

JMP Securities Maintains Market Outperform on HealthEquity, Raises Price Target to $117

HealthEquity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has fallen 6.83% since its last report. The company recently reported that it has 5.82 million shares sold short, which is 7.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749042030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HealthEquity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About HealthEquity?

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

After-Hours Center

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance.

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) raises FY2026 Adj EPS guidance from $3.57-$3.74 to $3.61-$3.78 vs $3.63 analyst estimate. Raises FY2026 sales outlook from $1.28 billion-$1.30 billion to $1.28 billion-$1.30 billion vs $1.30 billion estimate.

HealthEquity Raises FY2026 Adj EPS Guidance from $3.57-$3.74 to $3.61-$3.78 vs $3.63 Est; Raises FY2026 Sales Guidance of $1.28B-$1.30B vs $1.30B Est

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.88 by 10.23 percent. This is a 21.25 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $330.80 million which beat the analyst consensus estimate of $321.17 million by 3.00 percent. This is a 15.02 percent increase over sales of $287.60 million the same period last year.

Earnings Beats

HealthEquity Q1 Adj. EPS $0.97 Beats $0.88 Estimate, Sales $330.80M Beat $321.17M Estimate

<h3>Companies Reporting Before The Bell</h3>
• NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is likely to report quarterly loss at $0.22 per share on revenue of $1.71 billion. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is projected to report earnings for its first quarter. 
• Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $570.27 million. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is expected to report quarterly loss at $0.26 per share on revenue of $193.28 million. 
• Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is likely to report quarterly earnings at $2.29 per share on revenue of $7.45 billion. 
• Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $1.54 billion. 
• Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is estimated to report quarterly earnings at $1.46 per share on revenue of $10.25 billion. 
• Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) is likely to report quarterly earnings at $0.96 per share on revenue of $960.74 million. 
<h3>Companies Reporting After The Bell</h3>
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $113.64 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $279.91 million. 
• Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) is expected to report quarterly loss at $0.47 per share on revenue of $238.25 million. 
• Mama's Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $32.74 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.11 billion. 
• Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is estimated to report earnings for its first quarter. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $7.92 billion. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $320.41 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $185.47 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASAN

BASE

CTRN

MAMA

NESR

OLLI

SPWH

Earnings Scheduled For June 3, 2025

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-06-03. Here's what investors need to know before the announcement.
Analysts estimate that HealthEquity will report an earnings per share (EPS) of $0.89. 
The announcement from HealthEquity is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.03, leading to a 17.07% drop in the share price the following trading session.
Here's a look at HealthEquity's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.72</td>
<td>0.72</td>
<td>0.70</td>
<td>0.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.69</td>
<td>0.78</td>
<td>0.86</td>
<td>0.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872883_0.png" alt="eps graph" />
<h3>Performance of HealthEquity Shares</h3>
Shares of HealthEquity were trading at $100.61 as of May 30. Over the last 52-week period, shares are up 20.34%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on HealthEquity</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding HealthEquity.
With 8 analyst ratings, HealthEquity has a consensus rating of Outperform. The average one-year price target is $108.38, indicating a potential 7.72% upside.
<h3>Peer Ratings Comparison</h3>
The below comparison of the analyst ratings and average 1-year price targets of Alignment Healthcare, Progyny and Molina Healthcare, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $19.75, suggesting a potential 80.37% downside.</li>
<li>Analysts currently favor an Buy trajectory for Progyny, with an average 1-year price target of $24.5, suggesting a potential 75.65% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Molina Healthcare, with an average 1-year price target of $387.17, suggesting a potential 284.82% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Alignment Healthcare, Progyny and Molina Healthcare, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>18.84%</td>
<td>$189.04M</td>
<td>1.24%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>47.46%</td>
<td>$106.03M</td>
<td>-8.76%</td>
</tr>
<tr>
<td>Progyny</td>
<td>Buy</td>
<td>16.53%</td>
<td>$75.80M</td>
<td>3.39%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Outperform</td>
<td>12.24%</td>
<td>$1.28B</td>
<td>6.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
HealthEquity ranks first in revenue growth among its peers. It has the highest gross profit margin. HealthEquity's return on equity is the lowest among its peers.
<h3>All You Need to Know About HealthEquity</h3>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.84% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 8.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): HealthEquity's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.76%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/HQY/earnings">To track all earnings releases for HealthEquity visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: HealthEquity's Earnings Preview

Legal

Press Releases

If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

Financing

HealthEquity Community Foundation Awards $35,000 in New Grants

HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Barrington Research

Deutsche Bank

Goldman Sachs

RBC Capital

B of A Securities

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 시그넷 주얼러스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.</li>
<li>애널리스트들은 윌리엄스-소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)가 분기 실적을 주당 2.93달러, 매출을 23억 5천만 달러로 발표할 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 윌리엄스-소노마의 주식은 화요일에 1.6% 하락하여 172.28달러에 거래를 마쳤다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 화요일에 4분기 실적이 부진하다고 발표했다. 헬스에퀴티는 2026 회계연도 매출을 12억 8천만 달러에서 13억 5천만 달러로 예상하며, 이는 13억 1천만 달러에 대한 예상치와 일치한다. 이 회사는 연간 실적을 주당 3.57달러에서 3.74달러로 예상하며, 이는 주당 3.71달러에 대한 예상치와 일치합니다. 헬스에퀴티의 주식은 시간외 거래에서 13.7% 하락하여 87.75달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">여기에서 사전 시장 보도를 확인하세요</a>
<ul>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>)는 4분기 실적과 매출이 예상보다 좋았다고 보고했다. 스톤코의 주식은 시간외 거래에서 10.2% 상승하여 10.85달러에 거래되었다.</li>
<li>애널리스트들은 파이브 빌로우(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)가 분기 실적을 주당 3.38달러, 매출을 13억 9천만 달러로 발표할 것으로 예상하고 있다. 파이브 빌로우의 주식은 시간 외 거래에서 1.3% 상승하여 74.88달러에 거래되었다.</li>
</ul>
이것도 확인해보세요: <a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">이달에 포트폴리오를 구해줄 수 있는 상위 3개 소재 주식</a>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(18일) 장이 마감된 후 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 4분기 실적을 발표했고 애프터마켓에서 주가는 급락하고 있다. <a href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results" target="_blank" rel="noopener">실적 보고서</a>의 요약 내용은 다음과 같다.
<ul>
<li>4분기 매출: 3억 1,182만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener">예상치</a> 3억 605만 달러 상회</li>
<li>4분기 조정 주당순이익: 69센트, 예상치 72센트 하회</li>
</ul>
총 매출은 전년 동기 대비 19% 증가했다. 1월 31일 기준으로 990만 개의 건강저축계좌(HSA)가 개설되어 전년 대비 14% 증가했다. 1월 31일 기준 총 계좌 수는 1,700만 개를 기록했다. 총 HSA 자산은 전년 대비 27% 증가한 321억 달러였다.
헬스에퀴티는 2025회계연도에 보통주 140만 주를 1억 2,220만 달러에 재매입했다고 밝혔다. 1월 31일 기준으로 1억 7,780만 달러의 자사주 매입 잔액이 남아 있다.
헬스에퀴티 사장 겸 CEO인 스콧 커틀러(Scott Cutler)는 이렇게 말했다. &#8220;팀 퍼플(Team Purple)은 기록적인 매출과 전략적 이니셔티브 발전에서 큰 진전을 이루며 2025회계연도를 강력하게 마무리하여 2026회계연도에 대한 전망을 제공 할 수 있었다.&#8221;
"우리는 회원 우선의 안전한 모바일 경험에 중점을 두고 고객, 네트워크 파트너 및 회원을 위해 파트너십을 강화하고, 놀라운 경험을 제공하며, 회원 성과를 촉진하기 위한 3D 전략을 실행하고 있다."
가이던스: 헬스에쿼티는 2026회계연도 매출을 12억 8,000만~13억 5,000만 달러로 전망했으며, 예상치는 13억 1,000만 달러다. 연간 수익은 주당 3.57달러에서 3.74달러로 전망되며, 예상치는 주당 3.71달러다.
이러한 가이던스는 중간 지점에서 예상치보다 낮게 나왔으며, 이는 애프터마켓 주가에 부담을 주는 것으로 보인다.
HQY 주가 움직임: 주가는 화요일 애프터마켓에서 15.04% 하락한 86.38달러에 거래되고 있다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#8220;극단적 공포&#8221; 영역에 머물렀다.
미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.
월요일에 상승세를 나타냈음에도 불구하고, 미국 주식은 지난주 하락을 기록했다. 다우 지수는 약 3.1% 하락하여 2023년 3월 이후 최악의 주간 실적을 기록했고, S&amp;P 500은 2% 이상 하락하여 4주 연속 하락세를 나타냈다.
게스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) 주가는 회사가 WHP 글로벌로부터 주당 13달러 현금으로 회사를 인수하겠다는 비구속적 제안을 받았다고 발표한 후 월요일에 30% 급등했다. 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) 주가는 &#8216;어니 4.5&#8217; 및 딥씽킹 모델 &#8216;어니 X1&#8217;의 출시를 발표한 후 9% 상승했다.
경제지표 측면에서, 미국 소매판매는 2월에 전월 대비 0.2% 증가했으며, 시장 예상치 0.6% 상승에는 미치지 못했다. 단, 1월 소매판매는 1.2% 감소로 하향 수정되었다. NY 엠파이어 스테이트 제조업 지수는 3월에 26포인트 하락한 -20.0을 기록하며 2023년 5월 이후 최저치를 기록했다. NAHB/웰스파고 주택시장 지수는 3월에 39로 하락했으며, 2월에는 42를 기록했다.
S&amp;P 500 지수 대부분의 섹터는 월요일에 상승세를 보였고 특히 부동산, 에너지 및 필수소비재 섹터가 가장 큰 상승폭을 기록했다. 하지만 임의소비재 섹터는 시장 추세와 반대로 하락했다.
투자자들은 IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), 스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) 등의 실적 발표를 기다리고 있다.
다우존스는 월요일에 약 353포인트 상승하여 41,841.63포인트로 마감했다. S&amp;P 500은 0.64% 상승하여 5,675.12포인트로 상승했고, 나스닥 종합 지수는 월요일 거래 중 0.31% 상승하여 17,808.66포인트로 마감했다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 22.1로, 월요일에 &#8220;극단적 공포&#8221; 영역에 머물렀다. 이전 지수는 20.9였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 '극단적 공포' 영역

화요일(18일) 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자의 주목을 받을 수 있는 주식은 다음과 같다.
<ul>
<li>IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>): 화요일 개장 전 실적을 발표할 예정이며, 월가에서는 주당순이익 4센트, 매출 4억 2,400만 달러를 예상하고 있다. 주식은 월요일 애프터마켓에서 0.5% 상승하여 3.93달러에 거래되었다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>): 화요일 장 마감 후 실적을 발표할 예정이며, 주당순이익 72센트와 매출 3억 6,605만 달러를 발표할 것으로 예상된다. 주식은 월요일 애프터마켓에서 1.1% 상승하여 101.87달러에 거래되었다.</li>
<li>게티 이미지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>): 월요일에 4분기 긍정적인 실적을 발표했다. 주식은 월요일 애프터마켓에서 0.9% 하락하여 2.1301달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>상가모 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 예상보다 저조한 4분기 재무 실적을 발표했다. 주식은 월요일 애프터마켓에서 3% 하락하여 0.98달러에 거래되었다.</li>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>): 장 마감 후 실적을 발표할 예정이며, 분기 주당순이익 35센트와 매출 6억 4,756만 달러를 발표할 것으로 예상한다. 주식은 월요일 애프터마켓에서 0.1% 상승하여 10.20달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

SGMO

화요일 주목해야 할 주식: IHS 홀딩, 헬스에퀴티, 게티 이미지, 상가모 테라퓨틱스 및 스톤코

금요일 미국 증시는 S&amp;P 500 지수가 장중 2% 이상 급등하면서 상승세로 마감했다.
금요일의 상승에도 불구하고 지난주 증시는 주간 하락을 기록했다. 다우지수는 약 3.1% 하락하며 2023년 3월 이후 최악의 한 주를 기록했고, S&amp;P 500 지수는 2% 이상 하락하며 4주 연속 하락세를 기록했다.
월가 애널리스트들은 매일 새로운 종목을 추천하지만, 안타깝게도 모든 애널리스트가 시장 움직임을 예측하는 데 특별히 인상적인 실적을 가지고 있는 것은 아니다. 하나의 주식에 대해서도 애널리스트 의견 등급과 목표주가가 천차만별이기 때문에 투자자들은 어떤 애널리스트의 의견을 믿어야 할지 혼란스러울 수 있다.
벤징가의 애널리스트 주식 등급은 벤징가 뉴스 데스크가 주요 셀사이드(sell-side) 은행과의 직접 제휴를 통해 선별한 최고 품질의 주식 등급을 모아 놓은 것이다. 벤징가는 미국 주식 시장이 개장하기 3시간 전에 매일 밤새 변경된 등급을 표시한다. 투자 대시보드 제공업체인 Toggle.ai의 데이터 전문가들은 최근 벤징가 프로 구독자와 벤징가 독자들이 정기적으로 받는 애널리스트 인사이트가 주식 시장수익률 상회를 위한 트레이딩 지표로 성공적으로 사용될 수 있다는 사실을 밝혀냈다.
<h2>최고 애널리스트의 추천</h2>
다행히도 벤징가 독자라면 누구나 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie" target="_blank" rel="noopener">애널리스트 주식 등급</a> 페이지에서 최신 애널리스트 평가에 액세스할 수 있다. 트레이더가 벤징가의 방대한 애널리스트 주식 등급 데이터베이스를 정렬할 수 있는 방법 중 하나는 애널리스트 정확도이다. 벤징가 <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noopener">애널리스트 주식 평가</a>에 따르면 가장 정확한 월가 애널리스트 5명이 가장 최근에 추천한 종목을 살펴보자.
애널리스트: 트레버 왈시(Trevor Walsh)
<ul>
<li>애널리스트 회사: 시티즌즈 캐피털 마켓츠</li>
<li>평가 정확도: 85%</li>
<li>최신 평가: 3월 14일, 로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 시장수익률 등급 재확인</li>
<li>최근 뉴스: 3월 15일에 로켓랩은 바르다 스페이스 인더스트리(Varda Space Industries, Inc.)를 위한 세 번째 파이오니어(Pioneer) 우주선이 궤도에서 성공적으로 작동하고 있다고 발표했다.</li>
</ul>
애널리스트: 마크 휴즈(Mark Hughes)
<ul>
<li>애널리스트 회사: 트루이스트 증권</li>
<li>평가 정확도: 83%</li>
<li>최신 평가: 3월 11일, 제임스 리버 그룹 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>)에 대해 보유 등급을 유지하고 목표주가를 6달러에서 5달러로 하향 조정. 주식이 약 25% 급등할 것으로 예상.</li>
<li>최근 뉴스: 3월 4일 제임스 리버 그룹은 4분기 EPS 결과가 예상보다 저조하게 나타났다고 보고했다.</li>
</ul>
애널리스트: 롭 오웬스(Rob Owens)
<ul>
<li>애널리스트 회사: 파이퍼 샌들러</li>
<li>평가 정확도: 82%</li>
<li>최신 평가: 3월 13일, 센티넬원(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>)에 대해 비중확대 등급을 유지하고 목표주가를 32달러에서 28달러로 하향 조정. 주식이 52% 상승할 것으로 예상.</li>
<li>최근 뉴스: 3월 12일, 센티넬원은 4분기 매출이 2억 2,550만 달러로, 컨센서스 추정치인 2억 2,225만 달러를 초과했다고 발표했다.</li>
</ul>
애널리스트: 애론 레이커스(Aaron Rakers)
<ul>
<li>애널리스트 회사: 웰스파고</li>
<li>평가 정확도: 82%</li>
<li>최신 평가: 3월 13일, 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)에 대해 비중확대 등급을 유지하고 목표주가를 140달러에서 130달러로 하향 조정. 주식이 약 29% 상승할 것으로 예상.</li>
<li>최근 뉴스: 3월 5일, 마이크론은 마크 리우(Mark Liu)와 크리스티 시몬스(Christie Simons)를 이사회에 임명했다.</li>
</ul>
애널리스트: 알렉산더 패리스(Alexander Paris)
<ul>
<li>애널리스트 회사: 배링턴 리서치</li>
<li>평가 정확도: 81%</li>
<li>최신 평가: 3월 14일, 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)에 대해 시장수익률 상회폼등급을 유지하고 목표주가를 112달러로 설정. 주식이 약 15% 상승할 것으로 예상.</li>
<li>최근 뉴스: 2월 18일, 헬스에퀴티는 2025회계연도와 2026회계연도 가이던스를 확정했다.</li>
</ul>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

JRVR

RKLB

월가에서 가장 정확한 애널리스트의 지난주 추천 주식 5종목

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 헬로 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.
2. 분석가들은 Z스케일러(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)가 5억 6,793만 달러의 매출과 주당 69센트의 분기 이익을 기록할 것으로 예상한다. 회사는 시장이 마감된 후 실적을 발표할 예정이다. Z스케일러의 주식은 시간외 거래에서 0.1% 상승한 200.00달러를 기록했다.
3. 앱토즈 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>)의 주식은 회사가 한미약품(Hanmi Pharmaceutical Co.)와의 시설 계약을 통해 1천만 달러의 대출을 발표한 후 금요일 애프터마켓에서 상승했다. 앱토즈의 주식은 애프터마켓에서 69.3% 급등하여 0.6874달러에 거래되고 있다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 시장이 마감된 후 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 매출 2억 8,487만 달러에 주당 70센트의 분기 이익을 게시할 것으로 예상된다. 헬스에퀴티의 주가는 시간외 거래에서 0.6% 하락한 79.10달러를 기록했다.
5. 애널리스트들은 스포츠맨스 웨어하우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>)가 마감 후 2억 8,503만 달러의 매출과 주당 9센트의 분기 손실을 보고할 것으로 예상한다. 스포츠맨스 웨어하우스의 주가는 시간외 거래에서 1% 하락한 2.08달러를 기록했다.
이것도 확인해 보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">이번 분기에 폭발적으로 성장할 수 있는 2개 부동산 주식</a></li>
</ul>
AI 도구를 사용하여 생성한 이미지
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

APTO

MOMO

화요일 주목해야 할 주식: 헬로 그룹, Z스케일러, 앱토즈 그리고 2종목

헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 회사가 월요일 1분기 재무 결과를 발표한 후 주가가 상승했다. <a href="https://www.benzinga.com/pressreleases/24/06/g39145596/healthequity-reports-first-quarter-ended-april-30-2024-financial-results" target="_blank" rel="noopener">이 보고서</a>의 주요 내용을 살펴보자.
중요한 사항 (The Details): 헬스에퀴티는 분기별 주당 이익을 80센트로 보고했는데, 이는 애널리스트들의 합의 추정치인 66센트를 21.21% 상회했으며, 지난해 같은 기간보다 주당 이익인 50센트보다 60% 증가한 수치이다.
분기별 매출은 2억 8,760만 달러로 분석가 컨센서스 추정치인 2억 7,811만 달러를 넘어섰고, 이는 지난해 같은 기간의 매출 2억 4,443만 달러보다 17.66% 증가한 수치이다.
이 회사에 따르면 매출은 서비스 매출 1억1,820만 달러, 보관 매출 1억2,160만 달러, 교차 매출 4,770만 달러로 구성됐다. 2024년 4월 30일 현재 HSA는 910만 개로 전년 대비 13% 증가했으며, 여기에는 투자가 포함된 665,000개의 HSA가 포함되어 전년 대비 20% 증가했다. 2024년 4월 30일 기준 총 계정 수는 1,600만 개이며, 기타 소비자 지향 혜택 690만 개를 포함한다.
헬스에퀴티의 사장 겸 CEO인 존 케슬러(Jon Kessler)는 "기록적인 1분기 HSA 매출, 향상된 요금 적용 확대, 훌륭한 팀을 위한 베네핏월렛(BenefitWallet) 트랜치 3개 중 2개의 적시 전환이 2025 회계연도에 시작된다"고 말했다.
&#8220;성장과 마진 모두에 대한 추진력을 바탕으로 우리는 연간 지침을 높이고 놀라운 경험을 제공하고 파트너십을 심화하며 회원 성과를 높이기 위해 플랫폼 투자를 추진하고 있다.&#8221;
전망 (Outlook): 헬스에퀴티는 회계연도 이익을 주당 추정치 2.90달러 대비 주당 2.93~3.10달러로 전망하고, 회계연도 매출을 추정치 11억 6천만 달러 대비 11억 6천만~11억 8천만 달러로 예상한다.
HQY 주가 움직임: <a href="https://www.benzinga.com/stock/HQY#NASDAQ">Benzinga Pro</a>에 따르면, 이 회사의 주가는 월요일 시간외 거래에서 4.04% 상승한 84.50달러를 기록했다.

헬스에퀴티: 예상보다 좋은 제1분기 실적과 강력한 전망 발표 후 주가 상승

월요일 아침(현지 시간) 미국 주식 선물이 상승면서, 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 사이언스 애플리케이션 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>)가 개장 전에 분기별 이익을 주당 1.92달러, 매출 18억 4천만 달러로 보고할 것으로 예상하고 있다. SAIC 주식은 시간외 거래에서 3.4% 상승한 139.20달러를 기록했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)는 이사회 구성원인 엘리자베스 라파엘(Elizabeth Rafael)을 임시 CFO로 임명하고 1분기에 강력한 예비 결과를 발표했다. 이 회사는 시장 추정치인 주당 1.74달러에 비해 주당 1.87달러의 잠정 이익을 올렸고, 매출은 기대치인 13억 9,000만 달러에 비해 14억 2,000만 달러를 기록했다. 오토데스크의 주가는 시간외 거래에서 7.2% 상승한 216.04달러를 기록했다.</li>
<li>분석가들은 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)가 2억 7,811만 달러의 매출과 주당 66센트의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 실적을 발표할 예정이다. 헬스에퀴티의 주식은 시간외 거래에서 1.4% 상승한 82.79달러를 기록했다.</li>
</ul>
저희는 여기에서 <a href="https://www.benzinga.com/premarket/">개장 전 시장 정보를 확인하세요</a>
<ul>
<li>밍주 로지스틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>)는 옥실러스 글로벌(Oxylus Global) 인수에 합의했다고 발표했다. 밍주 로지스틱스의 주가는 시간외 거래에서 66.6% 급등한 0.5667달러를 기록했다.</li>
<li>분석가들은 라보로(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>)가 시장 마감 후 6억 1,907만 달러의 매출과 주당 3센트의 분기 이익을 기록할 것으로 예상합니다. 라보로의 주가는 시간외 거래에서 3.5% 하락한 5.77달러를 기록했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39111222/over-8m-bet-on-this-health-care-stock-check-out-these-4-stocks-insiders-are-buying">이 헬스케어 주식에 800만 달러 이상을 베팅하시겠습니까? 내부자들이 구매하고 있는 4가지 주식을 확인하세요.</a>

Comments

HealthEquity

뉴스

에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

수요일, 3월 19, 2025

화요일, 3월 18, 2025

월요일, 3월 17, 2025

화요일, 9월 03, 2024

월요일, 6월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌